Global pharma major Lupin Limited (Lupin) announced that its wholly owned subsidiary, Nanomi B.V. (‘Nanomi’), has signed a definitive agreement to acquirre VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners (GHO). The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin’s strategy to expand its European presence and advance its global specialty franchise.
VISUfarma’s established European operations will provide market expansion opportunities, direct presence and further business diversification across major European countries, including Italy, the UK, Spain, Germany and France. In addition, VISUfarma’s broad portfolio of 60+ branded ophthalmology products will present growth opportunities to accelerate Lupin’s expansion into the specialty segment across regions, and is projected to drive growth in Europe as well as in other markets.
Vinita Gupta, CEO of Lupin, said, “This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it also broadens our presence in Europe and further builds our specialty franchise in Ophthalmology.”
With the integration of VISUfarma, Lupin will offer a complete portfolio of products in the areas of dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and highly focused nutraceuticals prescribed by ophthalmologists. Lupin will finance the acquisition with existing cash on balance sheet.
Paolo Cioccetti, CEO Italy, VISUfarma, added, “As part of Lupin’s ophthalmology operations, we will build towards a global ophthalmology franchise with a commitment to advancing eye care and improving patient outcomes.”
